# The Race to Commercialize the World’s Most Powerful Psychedelic | WSJ Source: https://www.youtube.com/watch?v=9M-3vUxxxfA Recap page: https://rapidrecap.app/video/9M-3vUxxxfA Generated: 2026-07-30T03:57:27.714+00:00 --- ## The Gist AtiolBeckley and other biotech firms are racing to commercialize 5-MeO-DMT, a powerful psychedelic derived from toad venom, driven by surging market interest and federal backing. ## Quick Overview Biotech companies are investing heavily in developing synthesized 5-MeO-DMT and its analogues into FDA-approved treatments for major depressive disorder and treatment-resistant depression. With the psychedelic therapies market projected to reach 10 billion dollars by 2034, companies like AtaiBeckley and GH Research are advancing through clinical trials. Meanwhile, U.S. government officials, including HHS Deputy General Counsel Matt Zorn, are actively working to accelerate research and approvals. **Key Points:** - 5-MeO-DMT is secreted from the glands of the Colorado River toad and provides a profound psychedelic experience lasting about 30 minutes. - Atai Life Sciences and Beckley Psytech received U.S. FDA Breakthrough Therapy Designation for BPL-003, an intranasal formulation of 5-MeO-DMT. - The projected market for psychedelic therapies is expected to reach 10 billion dollars by 2034, driven by growing biotech investment. - Clinics like The Mission Within in Tijuana, Mexico, currently treat U.S. military veterans with 5-MeO-DMT for severe PTSD and depression. - Dr. David Lankri and researchers at Columbia University study the pharmacology of 5-MeO-DMT, noting it triggers two distinct serotonin receptors in the brain. - Johnson and Johnson's Spravato, an esketamine nasal spray, paved the way as the first commercially available FDA-approved psychedelic therapy. - President Trump signed an executive order in April 2026 to expand access and research into psychedelic therapies, accelerating review processes. ![Screenshot at 08:24: Projected Psychedelic Therapies Market by 2034 reaching 10 billion dollars.](https://ss.rapidrecap.app/screens/9M-3vUxxxfA/00-08-24.jpg) **Context:** Veterans and patients suffering from severe treatment-resistant mental health disorders often find conventional treatments like SSRIs ineffective. Many travel to clinics in Mexico to access psychedelic therapies like 5-MeO-DMT, prompting biotech companies and government agencies to pursue legal commercialization in the United States. ## Detailed Analysis The documentary details the booming industry surrounding the commercialization of 5-MeO-DMT, a potent psychedelic substance found in toad venom. It highlights the journey of veterans like Jeremy Tomlin and Billy Evans who traveled to Mexico to seek treatment at clinics like The Mission Within after traditional therapies failed. On the scientific front, researchers at Columbia University, including Dr. David Lankri, are synthesizing analogues and studying how the drug activates serotonin receptors to treat conditions like depression. Financially, the market is expanding rapidly, with companies like AtaiBeckley and GH Research advancing clinical trials. The regulatory landscape is also shifting, marked by FDA Breakthrough Therapy Designations and executive action by President Trump to streamline approvals, signaling a major paradigm shift in mental health treatment. ### The Retreat Experience in Tijuana U.S. veterans struggling with severe mental health issues travel to Mexico for psychedelic treatments. - Clinics such as The Mission Within in Tijuana offer 5-MeO-DMT sessions as a last resort for veterans failed by traditional talk therapy and SSRIs. - A 5-MeO-DMT session lasts approximately 30 minutes and can cause intense experiences, physical shaking, and profound emotional relief. - Veterans report that the treatment acts as a major reset, helping them overcome years of depression and PTSD. ![Screenshot at 04:36: A veteran recovering after a 5-MeO-DMT session at The Mission Within in Tijuana.](https://ss.rapidrecap.app/screens/9M-3vUxxxfA/00-04-36.jpg) ### Scientific Research at Columbia University Scientists are actively studying the chemical properties and mechanisms of 5-MeO-DMT. - Dr. David Lankri, an associate research scientist at Columbia University, has spent five years studying 5-MeO-DMT and its analogues. - Research shows that 5-MeO-DMT helps treat depression in animal models even after its psychedelic hallucinogenic effects are removed. - Scientists are working to understand how the drug interacts with serotonin receptors to develop safer and more accessible treatments. ![Screenshot at 06:12: Dr. David Lankri points out chemical structures of 5-MeO-DMT analogues on a laboratory glass board.](https://ss.rapidrecap.app/screens/9M-3vUxxxfA/00-06-12.jpg) ### The Commercial Market and Corporate Race Biotech companies are investing heavily to turn psychedelics into FDA-approved commercial medicines. - The market for psychedelic therapies is projected to reach 10 billion dollars by 2034 according to InsightAce Analytic. - Atai Life Sciences and Beckley Psytech secured U.S. FDA Breakthrough Therapy Designation for their intranasal 5-MeO-DMT formulation, BPL-003. - Competitor GH Research has multiple drug analogues in clinical trials, while biotech giant AbbVie acquires similar psychiatric therapy pipelines. ![Screenshot at 09:27: Clinical trial pipeline chart for GH Research showing compounds advancing through phases.](https://ss.rapidrecap.app/screens/9M-3vUxxxfA/00-09-27.jpg) ### Government Shifts and Regulatory Support Federal agencies are changing their stance on scheduling and expediting psychedelic research. - Matt Zorn, Deputy General Counsel for HHS, shifted from challenging government drug restrictions to working within the administration to speed up research. - In April 2026, President Trump signed an executive order to expand access and research into psychedelic therapies. - Proponents argue that these medicines offer a scalable, rapid-onset alternative to daily pills for millions of patients. ![Screenshot at 12:11: President Trump holding the signed executive order expanding psychedelic research in April 2026.](https://ss.rapidrecap.app/screens/9M-3vUxxxfA/00-12-11.jpg)